BINLUJAY
LIVE

Serial Number

98290546

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Xiomara Triana

Filing Date

Nov 29, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BINLUJAY Trademark

Serial Number: 98290546

BINLUJAY is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on November 29, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

November 29, 2023

Registration Date

Not Registered

Published for Opposition

May 20, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; pharmaceutical anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; biological diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 12, 2026 EXRA
SOU EXTENSION 1 GRANTED
Jan 12, 2026 EX1G
SOU EXTENSION 1 FILED
Jan 12, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 12, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 15, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 20, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 20, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 14, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 17, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 11, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 16, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 16, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 16, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 18, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 18, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 18, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 18, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 18, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 18, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 13, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 13, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 13, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 13, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 17, 2024 NWOS
NEW APPLICATION ENTERED
Nov 29, 2023 NWAP